ENPP2 Human

ENPP2, ATX, PDNP2, ATX-X, NPP2, PD-IALPHA, Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 isoform 2, ectonucleotide pyrophosphatase/phosphodiesterase 2, ENPP2, E-NPP 2, AUTOTAXIN, Extracellular lysophospholipase D, LysoPLD.

Ectonucleotide Pyrophosphatase-2, aka ENPP2, a part of the ectonucleotide pyrophosphatasefamily. ENPP2 is able to cut the phosphodiester bond between the alpha and the beta position of triphosphate nucleotides, acting as an ectonucleotide phosphodiesterase producing pyrophosphate, as most members of the ENPP family. It is unlike ENPP-1 and ENPP-3, has weak activity against nucleotides, but shows a lysophospholipase D activity which allows the formation of LPA and choline from lysophosphatidylcholine. As well, ENPP-2 and LPA are involved in several inflammatory-driven diseases such as arthritis and asthma.

ENPP2 Human Recombinant produced in HEK293 Cells is a single, glycosylated polypeptide chain containing 825 amino acids (49-863a.a) and having a molecular mass of 94.9kDa.
ENPP2 is fused to a 6 amino acid His-tag at C-terminus, and is purified by proprietary chromatographic techniques.

HEK293 Cells.

Sterile Filtered colorless solution.

The ENPP2 solution (0.25mg/ml) contains PBS (pH7.4) and 10% glycerol.

Store at 4°C if entire vial will be used within 2-4 weeks. Store, frozen at -20°C for longer periods of time. 
For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA).
Avoid multiple freeze-thaw cycles.

Greater than 90.0% as determined by SDS-PAGE.

Specific activity is greater than 15,000 units/mg, and defined as the amount of enzyme that hydrolyze 1nmole of bis (pNitrophenyl) phosphate per minute at pH8.7 at 37^℃.

DGSMDSPWTN ISGSCKGRCF ELQEAGPPDC RCDNLCKSYT SCCHDFDELC LKTARGWECT KDRCGEVRNE ENACHCSEDC LARGDCCTNY QVVCKGESHW VDDDCEEIKA AECPAGFVRP PLIIFSVDGF RASYMKKGSK VMPNIEKLRS CGTHSPYMRP VYPTKTFPNL YTLATGLYPE SHGIVGNSMY DPVFDATFHL RGREKFNHRW WGGQPLWITA TKQGVKAGTF FWSVVIPHER RILTILQWLT LPDHERPSVY AFYSEQPDFS GHKYGPFGPE MTNPLREIDK IVGQLMDGLK QLKLHRCVNV IFVGDHGMED VTCDRTEFLS NYLTNVDDIT LVPGTLGRIR SKFSNNAKYD PKAIIANLTC KKPDQHFKPY LKQHLPKRLH YANNRRIEDI HLLVERRWHV ARKPLDVYKK PSGKCFFQGD HGFDNKVNSM QTVFVGYGST FKYKTKVPPF ENIELYNVMC DLLGLKPAPN NGTHGSLNHL LRTNTFRPTM PEEVTRPNYP GIMYLQSDFD LGCTCDDKVE PKNKLDELNK RLHTKGSTEE RHLLYGRPAV LYRTRYDILY HTDFESGYSE IFLMPLWTSY TVSKQAEVSS VPDHLTSCVR PDVRVSPSFS QNCLAYKNDK QMSYGFLFPP YLSSSPEAKY DAFLVTNMVP MYPAFKRVWN YFQRVLVKKY ASERNGVNVI SGPIFDYDYD GLHDTEDKIK QYVEGSSIPV PTHYYSIITS CLDFTQPADK CDGPLSVSSF ILPHRPDNEE SCNSSEDESK WVEELMKMHT ARVRDIEHLT SLDFFRKTSR SYPEILTLKT YLHTYESEIH HHHHH

SDS